Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $6.20 · Revenue $7.50B · 11 analysts
Est. EPS $1.50 · Revenue $1.93B · 7 analysts
Est. EPS $1.61 · Revenue $1.96B · 3 analysts
Est. EPS $1.73 · Revenue $2.00B · 3 analysts
$1.01 per share
$1.01 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $6.9B | +6.7% | +2.3% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $1.3B | +1.1% | +6.8% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +52.4% | -3.4% | +0.9% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +21.3% | -6.9% | +8.7% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +18.8% | -5.3% | +4.3% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $1.2B | -16.1% | +18.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +16.6% | -21.4% | +15.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 49.8% | -17.9% | +13.9% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.96x | -6.3% | -2.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $12.7B | +7.4% | +6.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 4.57 vs 5.57 | -18.0% | 1.28 vs 1.49 | -14.0% |
| Revenue Surprise | $6.9B vs $6.9B | +0.4% | $1.9B vs $1.8B | +2.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | KIRKWOOD JONAH PREVOST | officer: Senior Vice President | Common Stock | D | 30 | $136.01 |
| Jun 3, 2026 | MCDONNELL PADRAIG | director, officer: President and CEO | Common Stock | D | 418 | $137.40 |
| Jun 2, 2026 | Downs Timothy Charles | officer: VP, Chief Accounting Officer | Common Stock | — | 0 | — |
| May 29, 2026 | Dolsten Mikael | director | Common Stock | D | 1,600 | $135.42 |
| May 19, 2026 | Buckner Michael Steven | officer: Senior Vice President | Common Stock | A | 8,872 | — |
Operator: Ladies and gentlemen, thank you for joining us, and welcome to the Q3 2026 Agilent Technologies, Inc. Earnings Conference Call. [Operator Instructions] I will now hand the call over to Tejas Savant, Head of Investor Relations. You may begin. Tejas Savant: Thank you, and welcome, everyone, to Agilent's conference call for the third quarter of fiscal year 2026. With me on the line are CEO, Padraig McDonnell; and CFO, Adam Elinoff. Joining for the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group; Angelica Riemann, President of the Agilent CrossLab Group; and Mike Zhang, President of the Applied Markets Group. This presentation is being webcast live. The press release for our third quarter financial results, investor presentation and information to supplement today's discussion, along with the recording of this webcast, are available on our website at investor.agilent.com. Today's comments will refer to non-GAAP financial measures. Non-GAAP measures are supplemental and should not be considered a substitute for GAAP results. You'll find the most directly comparable GAAP financial metrics and reconciliations in the press release and on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year and references to revenue growth are on a core or organic constant currency basis. All references to profitability metrics are on a non-GAAP basis. Core or organic constant currency revenue growth is adjusted for the impact of currency exchange rates and any acquisitions and divestitures completed within the past 12 months. Guidance is based on forecasted exchange rates. During this call, we will make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. Agilent assumes no obligation to update them. Please refer to the company's recent SEC filings for a more detailed description of the risks and other factors that could cause our performance to differ from these forward-looking statements. And now I'd like to turn the call over to Padraig. Padraig McDonnell: Thanks, Tejas, and welcome, everyone. We delivered an excellent third quarter with strong performance on both the top and bottom lines. Our results clearly demonstrate the sustained momentum unlocked by our exceptional commercial and operational execution and the Ignite Operating System against the backdrop of steadily improving end markets. For the third quarter, Agilent reported $1.88 billion in revenue, growing 7.3% on a core basis and exceeding the high end of our guidance by 140 basis points. Our operating margin of 27.2%, excluding the net benefit from tariff refunds, was 80 basis points ahead of our implied guidance of 26.4%, providing further evidence of the strong operating leverage and execution discipline embedded in the business. Including the net benefit from tariff refunds of $20 …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Padraig McDonnell | Chief Executive Officer, President & Director | USD 2,639,627 | Male | 1972 | Active |
Simon May | Senior VP and President of Life Sciences & Diagnostics Markets Group | USD 1,625,186 | — | 1973 | Active |
Michael Buckner | Senior Vice President, Chief Legal Officer, & Secretary | USD 1,176,848 | Male | — | Active |
Angelica Riemann | Senior VP & President of Agilent CrossLab Group | USD 1,124,756 | Female | 1971 | Active |
Rodney Gonsalves | Vice President of Finance | USD 832,080 | Male | 1966 | Active |
Frederick Schwarz | Senior VP, Chief Strategy & Corporate Development Officer | — | Male | — | Active |
Tim Downs | VP & Chief Accounting Officer | — | Male | 1981 | Active |
Adam S. Elinoff | Senior Vice President, Chief Financial Officer & Principal Financial Officer | — | Male | 1978 | Active |
August Specht | Senior Vice President & Chief Technology Officer | — | Male | — | Active |
Tejas Rajeev Savant | Vice President of Investor Relations | — | Male | — | Active |
Ashton Thomas Securities LLC grew its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 47.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,956 shares of the medical research company's stock after acquiring an additional 6,387 shares during
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.
NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.
